

HKSUO Uro-Oncology Asia 2020 Agenda

DAY 1 (11TH JAN 2020, SATURDAY)

11:30 (1 hr) Lunch symposium (By registration)

	Lecture: Overview of renal cancer management Prof. Sumanta K. Pal City of Hope Comprehensive Cancer Center, United States	Chairmen Dr. Law Ka Suet Princess Margaret Hospital, Hong Kong Dr. Tong Chi Chung Queen Mary Hospital, Hong Kong	Grand Ballroom IV
--	--	---	--------------------------

12:30 (25 mins)	Reception		Grand Ballroom III
-----------------	-----------	--	---------------------------


12:55 (5 mins)	Welcome remarks	Dr. Philip Kwong Hong Kong Society of Uro-Oncology, Hong Kong Dr. Xiao Guang Li Macau Oncology Association, Macau	Grand Ballroom III
----------------	-----------------	--	---------------------------

Prostate cancer session I

13:00 (30 mins)	Lecture 1: PARP inhibitor therapy: A paradigm shift in the treatment of mCRPC Q&A session Prof. Przemyslaw W. Twardowski John Wayne Cancer Institute at Providence Saint John's Health Center, United States	Chairmen Dr. Tim Chan Queen Elizabeth Hospital, Hong Kong Dr. Ma Wai Kit Hong Kong Urological Association, Hong Kong Dr. Xiang Hong Peng Macau Oncology Association, Macau	Grand Ballroom III
-----------------	--	---	---------------------------

13:30 (30 mins)	Lecture 2: The current management and utility of bone targeting agents in bone metastasis for prostate cancer Q&A session Associate Prof. Edmund Chiong National University Cancer Institute Singapore, Singapore		Grand Ballroom III
-----------------	---	--	---------------------------

14:00 (30 mins)	Lecture 3: Management of mHSPC: An evolving treatment paradigm Q&A session Dr. Laurence Krieger Northern Cancer Institute, Australia		Grand Ballroom III
-----------------	---	--	---------------------------

14:30 (30 mins)	 Tea break		
-----------------	---	--	--

15:00 (30 mins)	Abstract presentation	Presenters Dr. Lo Ka Lun The Chinese University of Hong Kong, Hong Kong Dr. So Tsz Him The University of Hong Kong, Hong Kong Dr. Barry Wo Tuen Mun Hospital, Hong Kong	Grand Ballroom III
-----------------	-----------------------	--	---------------------------

	Urinary tract tumour session	Grand Ballroom III	HKSUO and HKUA session	Grand Ballroom IV
--	-------------------------------------	---------------------------	-------------------------------	--------------------------

15:30 (30 mins)	Lecture 4: Who are good candidates for immunotherapy treatment for metastatic urothelial carcinoma? Q&A session Dr. Tim Chan Queen Elizabeth Hospital, Hong Kong	Chairmen Dr. Franklin Ho Hong Kong Urological Association, Hong Kong Dr. Henry Sze Private Oncologist, Hong Kong	Lecture 7: The emerging role of radiotherapy in metastatic prostate cancer Q&A session Associate Prof. Shankar Siva Peter MacCallum Cancer Centre, Australia	
-----------------	--	---	--	--

16:00 (30 mins)	Lecture 5: SBRT for RCC: Illusion or reality Q&A session Associate Prof. Shankar Siva Peter MacCallum Cancer Centre, Australia		Lecture 8 (HKSUO Special): Emerging role of fusion imaging with PSMA-PET and MRI in prostate cancer management Q&A session Dr. Gladys Lo Hong Kong Sanatorium & Hospital, Hong Kong	Chairmen Dr. Raymond Kan Hong Kong Urological Association, Hong Kong Dr. Angus Leung Private Oncologist, Hong Kong
-----------------	--	--	---	---

16:30 (30 mins)	Lecture 6: Advances in urothelial cancer: Evolving immunotherapy combination strategies Q&A session Dr. Enrique Grande MD Anderson Cancer Center Madrid, Spain		Lecture 9 (HKUA Special): Prostate cancer diagnosis: A shifting paradigm Q&A session Dr. Peter Chiu Prince of Wales Hospital The Chinese University of Hong Kong, Hong Kong	
-----------------	--	--	--	--

17:00	DAY 1 OF HKSUO URO-ONCOLOGY ASIA 2020 ENDS			
-------	---	--	--	--

HKSUO Uro-Oncology Asia 2020 Agenda

DAY 2 (12TH JAN 2020, SUNDAY)

Prostate cancer session II

08:00 (30 mins)	Reception		Grand Ballroom III
08:30 (30 mins)	Lecture 10: Radium-223 and bone health agents: Lesson learned in mCRPC Q&A session Dr. Angus Leung Private Oncologist, Hong Kong	Chairmen Dr. Cheung Foon Yiu Private Oncologist, Hong Kong Dr. Li Kin Macau Urological Association, Macau Dr. Darren Poon Prince of Wales Hospital, Hong Kong	Grand Ballroom III
09:00 (30 mins)	Lecture 11: Updates in the management for non-metastatic CRPC (nmCRPC) Q&A session Dr. Ravindran Kanesvaran National Cancer Centre Singapore, Singapore		Grand Ballroom III
09:30 (30 mins)	Lecture 12: GnRH agonist or antagonist for prostate cancer patients, are they the same? Q&A session Prof. David Crawford University of Colorado, United States		Grand Ballroom III



Tea break

Renal cell carcinoma session

10:00 (30 mins)	Tea break		
10:30 (30 mins)	Lecture 13: What is the optimal 1 st line treatment option in mRCC : IO-VEGF combination? Prof. Sumanta K. Pal City of Hope Comprehensive Cancer Center, United States	Chairmen Dr. Chan Kuen Hong Kong Society of Uro-Oncology, Hong Kong Dr. Cheung Man Hung Hong Kong Urological Association, Hong Kong Dr. Philip Kwong Hong Kong Integrated Oncology Centre, Hong Kong	Grand Ballroom III
11:00 (30 mins)	Lecture 14: What is the optimal 1 st line treatment option in mRCC : IO-IO combination? Prof. Bernard Escudier Institut Gustave Roussy, France		Grand Ballroom III
11:30 (30 mins)	Lecture 15: How to select optimal front-line treatment option in mRCC? Dr. Brian Rini Vanderbilt University Medical Center, United States		Grand Ballroom III
12:00 (30 mins)	Lecture 16: What is the optimal subsequent treatment option in mRCC with prior immunotherapy or TKI? Dr. Daniel Y.C. Heng Tom Baker Cancer Centre, Canada		Grand Ballroom III
12:30 (30 mins)	Panel discussion Prof. Bernard Escudier Dr. Daniel Y.C. Heng Prof. Sumanta K. Pal Dr. Brian Rini		Grand Ballroom III

13:00 (1 hr) Lunch symposium (By registration)

	Lecture: Evolution in management of CRPC with new AR agents Dr. Laurence Krieger Northern Cancer Institute, Australia	Chairmen Dr. Conrad Lee Private Oncologist, Hong Kong Dr. Eric Lee Tuen Mun Hospital, Hong Kong	Grand Ballroom IV
--	--	--	-------------------

14:00

DAY 2 OF HKSUO URO-ONCOLOGY ASIA 2020 ENDS